MA50518A - Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1 - Google Patents
Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1Info
- Publication number
- MA50518A MA50518A MA050518A MA50518A MA50518A MA 50518 A MA50518 A MA 50518A MA 050518 A MA050518 A MA 050518A MA 50518 A MA50518 A MA 50518A MA 50518 A MA50518 A MA 50518A
- Authority
- MA
- Morocco
- Prior art keywords
- insm1
- predicting
- expression
- therapeutic effect
- lsd1 inhibitor
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G01N33/575—
-
- G01N33/5758—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017108422 | 2017-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50518A true MA50518A (fr) | 2020-09-09 |
Family
ID=64454631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050518A MA50518A (fr) | 2017-05-31 | 2018-05-30 | Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12435128B2 (fr) |
| EP (1) | EP3633380A4 (fr) |
| JP (1) | JP6915056B2 (fr) |
| KR (1) | KR102291852B1 (fr) |
| AU (1) | AU2018276611B2 (fr) |
| MA (1) | MA50518A (fr) |
| TW (1) | TWI749235B (fr) |
| WO (1) | WO2018221555A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201804121RA (en) | 2015-11-27 | 2018-06-28 | Taiho Pharmaceutical Co Ltd | Novel biphenyl compound or salt thereof |
| DK3632443T3 (da) | 2017-05-26 | 2023-09-11 | Taiho Pharmaceutical Co Ltd | Potentiator af antitumorvirkning ved hjælp af en biphenylforbindelse |
| RU2765152C2 (ru) | 2017-05-26 | 2022-01-26 | Тайхо Фармасьютикал Ко., Лтд. | Новое соединение бифенила или его соль |
| MA50518A (fr) | 2017-05-31 | 2020-09-09 | Taiho Pharmaceutical Co Ltd | Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1 |
| BR112022008020A2 (pt) | 2019-11-13 | 2022-07-12 | Taiho Pharmaceutical Co Ltd | Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1 |
| WO2021107855A1 (fr) * | 2019-11-28 | 2021-06-03 | Amniotics Ab | Spécification de lignée définitive de guides de métabolisme pendant une transition d'endothéliale à hématopoïétique |
| EP4393919A1 (fr) * | 2022-12-27 | 2024-07-03 | Exscientia Al Limited | Modulateurs de lsd1 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8801518D0 (sv) | 1988-04-22 | 1988-04-22 | Astra Pharma Prod | A novel process |
| US6225049B1 (en) * | 1992-06-17 | 2001-05-01 | The United States Of America As Represented By The Department Of Health And Human Services | Human insulinoma-associated cDNA |
| CA2469649C (fr) | 2001-12-13 | 2011-05-03 | Natrogen Therapeutics, Inc. | Derives d'isoindigo, d'indigo et d'indirubine et utilisation de ceux-ci dans le traitement de cancer |
| EP2206517B1 (fr) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Compositions immunostimulantes contenant un anticorps anti-PD-L1 |
| EP1792622A1 (fr) | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Thérapie combinée antiproliférative comprenant un agent chimiothérapeutique à base de platine et d'inhibiteurs EGFR ou d'analogues de la pyrimidine |
| WO2010017047A1 (fr) | 2008-08-05 | 2010-02-11 | Merck & Co., Inc. | Composés thérapeutiques |
| EP2350317A4 (fr) | 2008-10-20 | 2012-06-27 | Univ Colorado Regents | Marqueurs biologiques prédictifs d une réponse anticancéreuse à des inhibiteurs de récepteur kinase de facteur de croissance 1 de type insuline |
| WO2010077624A1 (fr) | 2008-12-09 | 2010-07-08 | Merck Sharp & Dohme Corp. | Biaryl carboxamides |
| JP2012524280A (ja) | 2009-04-17 | 2012-10-11 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 上皮成長因子受容体キナーゼ阻害剤に対する抗がん反応を予測するための生物学的マーカー |
| AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| CN102985402B (zh) | 2010-04-20 | 2015-04-29 | 罗马大学 | 反苯环丙胺衍生物作为组蛋白去甲基酶lsd1和/或lsd2的抑制剂 |
| EP3375775A1 (fr) * | 2010-07-29 | 2018-09-19 | Oryzon Genomics, S.A. | Inhibiteurs de déméthylase de lsd1 a base de arylcyclopropylmines et leur utilisation médicale |
| PE20141322A1 (es) | 2011-03-25 | 2014-10-05 | Glaxosmithkline Intellectual Property (N 2) Limited | Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina |
| US9345767B2 (en) * | 2011-05-16 | 2016-05-24 | Taiho Pharmaceutical Co., Ltd. | Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and EGFR inhibitor |
| EP3736265A1 (fr) | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | Composés (hétéro)aryl cyclopropylamine comme inhibiteurs de lsd1 |
| WO2014151761A1 (fr) | 2013-03-15 | 2014-09-25 | Ariad Pharmaceuticals, Inc. | Nouveaux inhibiteurs de choline kinase |
| BR112016002496B1 (pt) * | 2013-08-06 | 2022-07-12 | Imago Biosciences Inc. | Composto e composição farmacêutica |
| US9266907B2 (en) | 2013-09-05 | 2016-02-23 | King Abdullah University Of Science And Technology | Tunable rare-earth fcu-metal-organic frameworks |
| SMT202300014T1 (it) | 2013-12-11 | 2023-05-12 | Celgene Quanticel Research Inc | Inibitori della demetilasi lisina-specifica-1 |
| WO2015103060A1 (fr) | 2014-01-06 | 2015-07-09 | Algomedix, Inc. | Modulateurs de trpa1 |
| AU2015253040B2 (en) | 2014-05-01 | 2020-04-09 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| EP3185858A4 (fr) | 2014-08-25 | 2017-12-27 | University of Canberra | Compositions pour moduler les cellules souches cancéreuses et leurs utilisations |
| BR112017004334A2 (pt) | 2014-09-05 | 2018-08-07 | Celgene Quanticel Res Inc | inibidores de desmetilase específica de lisina-1. |
| CN107750167B (zh) | 2015-04-20 | 2021-05-25 | 效应物治疗公司 | 用于治疗癌症和感染的免疫检查点调节剂的抑制剂 |
| WO2017013061A1 (fr) * | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarqueurs associés à des inhibiteurs de lsd1 et utilisations de ceux-ci |
| CN105233292B (zh) * | 2015-10-19 | 2018-03-13 | 中国科学院北京基因组研究所 | Ory‑1001联合放疗和化疗用于治疗人三阴性乳腺癌的用途 |
| SG11201804121RA (en) | 2015-11-27 | 2018-06-28 | Taiho Pharmaceutical Co Ltd | Novel biphenyl compound or salt thereof |
| US20200069677A1 (en) * | 2016-12-09 | 2020-03-05 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| WO2018136961A1 (fr) | 2017-01-23 | 2018-07-26 | Syros Pharmaceuticals Inc. | Méthodes de traitement de patients à l'aide d'un agoniste du récepteur alpha de l'acide rétinoïque et d'un anticorps anti-cd38 |
| RU2765152C2 (ru) | 2017-05-26 | 2022-01-26 | Тайхо Фармасьютикал Ко., Лтд. | Новое соединение бифенила или его соль |
| DK3632443T3 (da) | 2017-05-26 | 2023-09-11 | Taiho Pharmaceutical Co Ltd | Potentiator af antitumorvirkning ved hjælp af en biphenylforbindelse |
| MA50518A (fr) | 2017-05-31 | 2020-09-09 | Taiho Pharmaceutical Co Ltd | Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1 |
| LT3644999T (lt) | 2017-06-30 | 2023-03-10 | Celgene Corporation | 2-(4-chlorfenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il) metil)-2,2-difluoracetamido kompozicijos ir panaudojimo būdai |
| WO2019075327A1 (fr) * | 2017-10-12 | 2019-04-18 | Dana-Farber Cancer Institute, Inc. | Traitement du carcinome à cellules de merkel |
| US11685782B2 (en) | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
| AU2018377852B2 (en) | 2017-11-29 | 2022-03-24 | Epiaxis Therapeutics Pty Ltd | Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist |
| WO2019136016A1 (fr) | 2018-01-02 | 2019-07-11 | Celgene Corporation | Isotopologues de 2-(4-chlorophényl)-n-((2-(2,6-dioxopipéridin-3-yl)-1-oxoisoindolin-5-yl)méthyl)-2,2-difluoroacétamide |
| KR102737283B1 (ko) | 2019-07-17 | 2024-12-03 | 서밋 (옥스포드) 리미티드 | 리디닐라졸 및 이의 결정 형태의 제조방법 |
| BR112022008020A2 (pt) | 2019-11-13 | 2022-07-12 | Taiho Pharmaceutical Co Ltd | Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1 |
| AU2021230575A1 (en) | 2020-03-06 | 2022-10-20 | Celgene Quanticel Research, Inc. | Combination of an LSD-1 inhibitor and nivolumab for use in treating SCLC or sqNSCLC |
-
2018
- 2018-05-30 MA MA050518A patent/MA50518A/fr unknown
- 2018-05-30 WO PCT/JP2018/020667 patent/WO2018221555A1/fr not_active Ceased
- 2018-05-30 JP JP2019521254A patent/JP6915056B2/ja active Active
- 2018-05-30 KR KR1020197038128A patent/KR102291852B1/ko active Active
- 2018-05-30 TW TW107118546A patent/TWI749235B/zh active
- 2018-05-30 US US16/617,866 patent/US12435128B2/en active Active
- 2018-05-30 AU AU2018276611A patent/AU2018276611B2/en active Active
- 2018-05-30 EP EP18809220.9A patent/EP3633380A4/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018276611A1 (en) | 2020-01-16 |
| AU2018276611B2 (en) | 2022-01-06 |
| US12435128B2 (en) | 2025-10-07 |
| JPWO2018221555A1 (ja) | 2020-05-21 |
| KR20200007975A (ko) | 2020-01-22 |
| WO2018221555A1 (fr) | 2018-12-06 |
| US20200190175A1 (en) | 2020-06-18 |
| EP3633380A1 (fr) | 2020-04-08 |
| KR102291852B1 (ko) | 2021-08-23 |
| TWI749235B (zh) | 2021-12-11 |
| JP6915056B2 (ja) | 2021-08-04 |
| TW201907162A (zh) | 2019-02-16 |
| RU2019144056A (ru) | 2021-07-02 |
| EP3633380A4 (fr) | 2021-02-24 |
| RU2019144056A3 (fr) | 2021-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3633380A4 (fr) | Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1 | |
| IL283639A (en) | Kif18a inhibitors | |
| IL282794A (en) | Therapeutic methods | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| EP3857879A4 (fr) | Simplification de prédiction inter-intra combinée | |
| EP3952243A4 (fr) | Procédé et appareil d'accès aléatoire | |
| IL262814A (en) | Combination therapies of hdac inhibitors and pd-1 inhibitors | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| FR3052891B1 (fr) | Procede d'estimation du facteur d'intensite des contraintes et procede de calcul de duree de vie associe | |
| EP3624804A4 (fr) | Inhibiteurs des histone désacétylases (hdac) | |
| EP3745802A4 (fr) | Procédé et dispositif d'accès aléatoire | |
| PL3662234T3 (pl) | Urządzenie i sposób ulepszonego monitorowania oprysku | |
| EP3801499A4 (fr) | Inhibiteurs de sarm1 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| HUE063986T2 (hu) | Eljárás és berendezés predikcióhoz | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| HUE062990T2 (hu) | DMVR és BDOF alapú inter predikciós eljárás és készülék | |
| MA47305A (fr) | Inhibiteurs bicycliques d'histone désacétylase | |
| SG11202006441SA (en) | Agents and methods for predicting response to therapy | |
| EP3415524A4 (fr) | INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE | |
| FR3026440B1 (fr) | Procede de suppression d'effet pogo | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |